沃华医药: 2025年半年度业绩预告

Performance Forecast - The company expects a net profit of 37 million to 53 million yuan for the period from January 1, 2025, to June 30, 2025, representing an increase of 233.89% to 378.27% compared to the same period last year, where the net profit was 11.0815 million yuan [1][2] - The expected net profit after deducting non-recurring gains and losses is projected to be between 34.2 million and 48.5 million yuan, which is an increase of 247.96% to 393.45% compared to the previous year's figure of 9.8287 million yuan [1][2] - The basic earnings per share are anticipated to be between 0.0641 yuan and 0.0918 yuan, compared to 0.0192 yuan per share in the same period last year [1] Reasons for Performance Change - The company has adapted to changes in the market environment, implemented various collaborative marketing models, and adjusted its market layout, resulting in a year-on-year increase in revenue [2] - Cost control measures have been effective, with a reduction in the procurement costs of key raw materials and the ongoing implementation of "cost reduction and efficiency enhancement" initiatives, leading to a significant improvement in operating profit [2]